Xenon Pharmaceuticals Inc. (XENE)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Xenon Pharmaceuticals Inc. (XENE) is up 22.2% since the beginning of the year. At $55 per share, XENE is trading 14.3% below its 52-week high of $64. Investors who bought $1,000 worth of XENE shares 5 years ago would now be looking at an investment worth $3,044.

Xenon Pharmaceuticals Inc. (XENE) has returned 22.24% so far this year and 70.95% over the past 12 months. Looking at the last ten years, XENE has achieved an annualized return of 24.15%, outperforming the S&P 500 Index benchmark, which averaged 13.88% per year.

Based on dividend-adjusted daily data since Nov 5, 2014, XENE's average daily return is +0.14%, while the average monthly return is +2.58%. At this rate, an investment would double in approximately 2.3 years.

Historically, 49% of months were positive and 51% were negative. The best month was Oct 2021 with a return of +103.9%, while the worst month was Mar 2017 at -50.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.

On a daily basis, XENE closed higher 48% of trading days. The best single day was Oct 4, 2021 with a return of +101.9%, while the worst single day was Mar 24, 2017 at -52.8%.

Xenon Pharmaceuticals Inc. has an annualized alpha of 27.59%, beta of 0.84, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since November 05, 2014.

• This stock captured 115.90% of S&P 500 Index gains and 100.25% of its losses - amplifying both gains and losses, but participating more in upside than downside.
• R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

XENE ranks 85 for risk / return — in the top 85% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Xenon Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Xenon Pharmaceuticals Inc. was 90.43%, occurring on Nov 14, 2017. Recovery took 977 trading sessions.

The current Xenon Pharmaceuticals Inc. drawdown is 12.70%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Xenon Pharmaceuticals Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Xenon Pharmaceuticals Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.